Participated · Series B · Sep 2025

Mercy BioAnalytics develops extracellular vesicle–based liquid biopsy tests aimed at the early detection of cancer. Its patented Mercy Halo platform uses biomarker co-localization to interrogate abundant blood-based extracellular vesicles that carry cancer signatures from their cell of origin. The company’s initial focus is the early detection of ovarian and lung cancers, and its blood-based ovarian cancer test portfolio is designed to detect pre-clinical high grade serous ovarian carcinoma in post-menopausal women. Mercy says the Mercy Halo ovarian cancer screening test shows unprecedented sensitivity and specificity in a blinded evaluation of samples from a randomized controlled trial. The company plans to commercialize its ovarian cancer tests and expand the Mercy Halo portfolio to include multi-cancer and lung cancer screening tests. Mercy is based in Waltham, Mass., and recently closed a financing to support commercialization and portfolio expansion. Mercy BioAnalytics is advancing the Mercy Halo extracellular vesicle‑based liquid biopsy platform to enable early detection of cancer. Mercy Halo seeks high clinical sensitivity and specificity by simultaneously detecting multiple cancer‑related biomarkers co‑localized on individual tumor‑derived extracellular vesicles. The test can be run on a very small volume of serum or plasma and uses a simple PCR‑based readout. The company closed an oversubscribed $41 million Series A to advance development and commercialization, with an initial focus on high‑risk lung cancer screening. Proceeds will also support clinical programs in ovarian cancer and the development of a broader portfolio of early‑detection tests. Preliminary data presented at ASCO, AACR and EDCC demonstrated promising performance for detecting Stage I and II lung and ovarian cancers, and Mercy is planning larger independent validation studies.

Participated · Seed · Feb 2025

Terrain Biosciences builds tools and services to design and manufacture high-quality RNA for RNA therapeutics and vaccines. The company offers a catalog of commonly used sequences, custom RNA builds, and AI-guided sequence design tools to optimize sequences for safety, efficacy, and manufacturability. It leverages recent innovations in protein and RNA design and uses experimental data to train novel machine-learning models for RNA sequence design. Terrain positions its platform as a sandbox for scientists to design and build sequences faster and with higher confidence. The company says these capabilities support drug developers through every step of the journey to the clinic and beyond. It is led by CEO Chetan Tadvalkar and was founded by Omar Abudayyeh, Jonathan Gootenberg, and Patrick Hsu.

Participated · Seed · Feb 2025

Akribion Therapeutics develops a proprietary G-dase® E nuclease platform that enables RNA-guided, nuclease-based programmable cell depletion by shredding DNA and RNA only when a guide RNA matches an intracellular RNA sequence. The technology is designed to kill only targeted cells while leaving healthy cells unharmed. The company was founded in 2024, spun out of BRAIN Biotech AG, and is based in Zwingenberg, Germany. Akribion is initially focused on precision oncology, specifically HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), and is exploring applications in other oncology indications as well as autoimmune diseases, fibrosis, and infectious diseases. The platform’s guide-RNA-driven adaptability is positioned to speed target switching and accelerate development compared with traditional approaches. A recent seed financing is intended to advance the program toward in vivo proof of concept.

Participated · Series D · Nov 2024

PrognomiQ develops multi-omics liquid biopsy tests that combine deep proteomics with genomics, metabolomics, epigenomics, transcriptomics, cell-free DNA, RNA, metabolites, and lipids to identify biomarkers for cancer and other complex diseases. The company leverages Seer’s Proteograph™ Product Suite and was spun out of Seer in September 2020. PrognomiQ is advancing an early detection lung cancer test intended first as a lab-developed test (LDT) and later as an in vitro diagnostic (IVD), and it has obtained a CLIA license to support LDT development. It is currently enrolling a prospective 15,000-subject lung cancer study, initiated in 2023, to support IVD registration. Earlier research from a 2,513-subject case-control study demonstrated 89% sensitivity and 89% specificity in the validation cohort, including 80% sensitivity for stage 1 lung cancer. The company has raised more than $135 million since its founding and is based in San Mateo, Calif. PrognomiQ develops and commercializes multi-omics human tests using proteomics, metabolomics and genomics technologies to generate deep biological insights into cancer mechanisms and host response. The company generates rich phenotypic proteomic and metabolomics information and complements this with large-scale genomics data to improve detection, treatment selection and monitoring of complex diseases. PrognomiQ intends to use the new funding to accelerate development of its platform and its pipeline of multi-omics products focused on multiple cancers. The company was founded in September 2020 and is led by CEO Philip Ma. Financially, the announced round brings its total funding to more than $101M, including the latest $46M financing announced in March 2022. PrognomIQ was spun out of Seer to develop and commercialize multi-omics human tests that leverage proteomics alongside genomics and metabolomics. The company plans to use Seer’s Proteograph data to provide functional protein context for genetic variation and to create differentiated multi-omics approaches for early detection, treatment monitoring, and recurrence monitoring of disease. PrognomIQ intends to combine protein-level information with other omics to improve test performance for cancer and other complex diseases. Seer has demonstrated Proteograph utility in early disease detection in a proof-of-concept non-small cell lung cancer study published in Nature Communications. Seer retains approximately 19% minority ownership in PrognomIQ after the spin-out. Philip Ma, Ph.D., founder and former Chief Business Officer of Seer, is the newly appointed CEO of PrognomIQ.

Participated · Series A · Dec 2023

Tome Biosciences develops programmable genomic integration (PGI) technologies to insert genetic sequences of any size at specific genomic locations for integrative gene and cell therapies. Its lead PGI approach, integrase-mediated PGI (I-PGI), is based on PASTE technology discovered by co‑founders Omar Abudayyeh and Jonathan Gootenberg at MIT and combines CRISPR/Cas9 site-specificity with integrases to insert DNA without double-strand breaks. Tome has demonstrated site-specific insertions of more than 30 kb in multiple dividing and non-dividing cell types and can multiplex edits to enable complex cell engineering. The company holds an exclusive license to the core PASTE technology and lists U.S. patents 11,572,556; 11,827,881; and 11,834,658. Led by President and CEO Rahul Kakkar, Tome plans to use the new capital to develop integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases. The company raised $213M in Series A and Series B financings and operates in the genomic medicines field focused on delivering curative therapies.